Delphi Genetics SA (“Delphi”) has announced today a broad licensing agreement
with a subsidiary of Merck & Co., Inc., known as MSD outside the United States
and Canada, for the use of the StabyExpress™ technology, which allows high
yield, cost effective protein expression without the use of antibiotics.
Under the agreement, Merck receives a non-exclusive license to use the
StabyExpress™ technology for protein expression in research and product
development. In exchange, Delphi is eligible to receive milestone payments
associated with the development of Merck product candidates that utilize the
StabyExpress™ technology, as well as royalties on sales of such products. The
financial details of the agreement were not disclosed.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in